Loading clinical trials...
Loading clinical trials...
To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT04161248 · Lymphoma, B-Cell
NCT06528301 · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), and more
NCT06008691 · Non-Hodgkin Lymphoma, B-cell
NCT05940272 · Lymphoma, B-Cell, Lymphoma, and more
NCT06534437 · Non-Hodgkin Lymphoma, B-cell
UAB CCC Clinical Studies Unit
Birmingham, Alabama
University of Alabama at Birmingham Kirklin Clinic
Birmingham, Alabama
UAB Russell Ambulatory Pharmacy
Birmingham, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions